Frequency of frontotemporal dementia gene variants in C9ORF72, MAPT, and GRN in academic versus commercial laboratory cohorts
Authors Steele NZR, Bright AR, Lee SE, Fong JC, Bonham LW, Karydas A, Karbassi ID, Pribadi M, Meservey MA, Gallen MC, Ramos EM, Liaquat K, Hoffman CC, Krasner MR, Dodge W, Miller BL, Coppola G, Rankin KP, Yokoyama JS, Higgins JJ
Received 29 January 2018
Accepted for publication 5 July 2018
Published 25 October 2018 Volume 2018:8 Pages 23—33
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Justinn Cochran
Peer reviewer comments 3
Editor who approved publication: Dr John Martignetti
Natasha ZR Steele,1,2 Alison R Bright,3 Suzee E Lee,1 Jamie C Fong,1 Luke W Bonham,1 Anna Karydas,1 Izabela D Karbassi,3 Mochtar Pribadi,4 Marc A Meservey,3 Matthew C Gallen,3 Eliana Marisa Ramos,5 Khalida Liaquat,3 Carol C Hoffman,3 Meagan R Krasner,3 Whitney Dodge,3 Bruce L Miller,1 Giovanni Coppola,4,5 Katherine P Rankin,1 Jennifer S Yokoyama,1,* Joseph J Higgins3,*
1Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA; 2School of Medicine, University of Washington, Seattle, WA, USA; 3Quest Diagnostics, Neurology Franchise, Marlborough, MA, USA; 4Department of Neurology, University of California, Los Angeles, CA, USA; 5Department of Psychiatry, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA
*These authors contributed equally to this work
Background: Frontotemporal lobar degeneration (FTLD) is a leading cause of dementia, and elucidating its genetic underpinnings is critical. FTLD research centers typically recruit patient cohorts that are limited by the center’s specialty and the ways in which its geographic location affects the ethnic makeup of research participants. Novel sources of data are needed to get population estimates of the contribution of variants in known FTLD-associated genes.
Methods: We compared FLTD-associated genetic variants in microtubule-associated protein tau (MAPT), progranulin (GRN), and chromosome nine open reading frame 72 (C9ORF72) from an academic research cohort and a commercial clinical genetics laboratory. Pathogenicity was assessed using guidelines of the American College of Medical Genetics and Genomics and a rule-based DNA variant assessment system. We conducted chart reviews on patients with novel or rare disease-associated variants.
Results: A total of 387 cases with FTLD-associated variants from the commercial (n=2,082) and 78 cases from the academic cohort (n=2,089) were included for analysis. In the academic cohort, the most frequent pathogenic variants were C9ORF72 expansions (63%, n=49), followed by GRN (26%, n=20) and MAPT (11%, n=9). Each gene’s contribution to disease was similarly ranked in the commercial laboratory but differed in magnitude: C9ORF72 (89%, n=345), GRN (6%, n=24), and MAPT (5%, n=19). Of the 37 unique GRN/MAPT variants identified, only six were found in both cohorts. Clinicopathological data from patients in the academic cohort strengthened classification of two novel GRN variant as pathogenic (p.Pro166Leufs*2, p.Gln406*) and one GRN variant of unknown significance as a possible rare risk variant (p.Cys139Arg).
Conclusion: Differences in gene frequencies and identification of unique pathogenic alleles in each cohort demonstrate the importance of data sharing between academia and community laboratories. Using shared data sources with well-characterized clinical phenotypes for individual variants can enhance interpretation of variant pathogenicity and inform clinical management of at-risk patients and families.
Keywords: frontotemporal dementia, genetics, cognitive disorders, dementia, aging, attributable risk, variant classification
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]